Combination of Endoglin and ASCVD Risk Assessment Improves Carotid Subclinical Atherosclerosis Recognition

Qiaowei Li¹, Fan Lin¹, Douli Ke¹, Qiong Cheng², Yongzhi Gui¹, Yuyan Zhou¹, Yicheng Wu¹, Yinzhou Wang² and Pengli Zhu¹

Qiaowei Li and Fan Lin contributed equally to this work.

¹Shengli Clinical Medical College of Fujian Medical University, Department of Geriatric Medicine, Fujian Provincial Hospital, Fujian Institute of Clinical Geriatrics, Fujian Provincial Center for Geriatrics.
²Department of Neurology, Fujian Provincial Hospital, Fujian Provincial Center for Geriatrics, Shengli Clinical Medical College of Fujian Medical University.

Aim: Our study investigated the association between soluble endoglin and carotid subclinical atherosclerosis.

Methods: We used endoglin as an adjunct to atherosclerotic cardiovascular disease (ASCVD) risk, in recognition of carotid clinical atherosclerosis, in order to explore a new model to refine risk assessment. Out of 3,452 participants, 978 subjects with detected soluble endoglin were enrolled in a cross-sectional investigation in Fujian Province were enrolled. Soluble endoglin concentration in serum samples was evaluated using an enzyme-linked immunosorbent assay method. Carotid ultrasonography was used to detect intima-media thickness and carotid plaque.

Results: The mean 10-year ASCVD risk by the new Pooled Cohort Equations accounted for 10.04% (±12.35). The mean soluble endoglin level was 15.35 ng/ml (±6.64). Multivariable regression demonstrated that age, systolic blood pressure, diastolic blood pressure, total cholesterol, high density lipoprotein cholesterol, and serum uric acid were independent determinants of soluble endoglin. Adding tests of ASCVD and endoglin together, in parallel, will increase the sensitivity and decrease specificity in recognizing carotid subclinical atherosclerosis. Evaluating the added value of endoglin to the ASCVD risk model showed significantly improved discrimination with analysis of C-statistics, continuous net reclassification index and integrated discrimination index. Both ASCVD risk and soluble endoglin showed positively linear correlation with carotid intima-media thickness (cIMT) (β = 0.006, P < 0.001; β = 0.485, P < 0.001). Even with adjustment for other factors, the relationship between log-transformed soluble endoglin with cIMT was still significant (β = 0.369, P < 0.001).

Conclusions: The combination of ASCVD risk and endoglin levels increases carotid atherosclerosis recognition.

Key words: Carotid subclinical atherosclerosis, Cardiovascular disease risk factors, Endoglin

Introduction

Over the past several decades, the Chinese population has experienced increased incidence of cardiovascular disease¹, ², especially from myocardial infarction and stroke³. Many previous reports have proven that carotid subclinical atherosclerosis, including elevated carotid intima-media thickness (cIMT) and carotid plaque, is an independent risk factor of myocardial infarction, coronary heart disease, and stroke⁴,⁶. Even in low Framingham risk subjects, initial screening by cIMT and plaque assessment is likely to improve subclinical atherosclerosis detection⁷. The American College of Cardiology/American Heart Association recommended new equations to estimate the 10-year risk for developing initial atherosclerotic
cardiovascular disease (ASCVD) events (defined as first occurrence of nonfatal myocardial infarction or coronary heart disease death, or fatal or nonfatal stroke) in 2013. Until now, the association of 10-year ASCVD risk with carotid subclinical atherosclerosis has been well demonstrated. However, whether potential novel markers could improve the utility and accuracy of ASCVD risk assessment is still under exploration.

Endoglin (CD105, TGF-β receptor III) is a transmembrane glycoprotein, mainly expressed on activated vascular endothelial cells, as a marker of tumor microvessels and is associated with solid tumor progression. The soluble form of endoglin is generated by cleavage of the extracellular domain from the intact membrane by metalloprotease, may downregulate eNOS expression, and serves as a natural antagonist for TGF-β signaling.

Recently, soluble endoglin was shown to have a role in endothelial injury, activation, inflammation, and senescence; it could contribute to preeclampsia, hypertension, diabetes mellitus, and hypercholesterolemia. In addition, soluble endoglin could be a marker for predicting atherosclerosis. Blann et al. first reported soluble endoglin levels were higher in peripheral arterial disease patients, but not in coronary artery disease (CAD) patients, than in controls. Li et al. stated the circulating concentration of soluble endoglin increased in early stages of atherosclerosis, due to damage of endothelial cells, and then decreased in later stages. However, Cruz-Gonzalez et al. investigated soluble endoglin levels in 183 patients with acute myocardial infarction. They found soluble endoglin levels in acute myocardial infarction patients were low and decreased further after acute myocardial infarction. A recent study showed that CAD patients had low soluble endoglin levels in circulation, especially patients with 3-vessel disease. The study also demonstrated an inverse association between soluble endoglin and the severity of coronary atherosclerosis. Taking those controversial results into account, investigating the association between soluble endoglin and subclinical atherosclerosis would elucidate endoglin’s effect on atherosclerosis progression.

Thus, our study aimed to investigate the association between soluble endoglin and carotid subclinical atherosclerosis. Furthermore, we used the ASCVD risk as an adjunct to endoglin in recognition of carotid subclinical atherosclerosis in order to explore a new model to refine risk assessment.

**Methods**

Our study was in a framework of stroke research involving 4,932 participants. Cluster sampling was performed from May 2016 to May 2017. We randomly selected participants from Xing village in Wuyishan City, the Xiangcheng District, Zhangzhou City, the Dongjie community, Gulou District, and Qingkou Township, Minhou County, Fuzhou City, for this cross-sectional investigation. All participants were required to complete a standardized questionnaire, carotid ultrasonography, anthropometric, and biochemical measurements. Voluntary participants aged 40 years and above living in their current place of residence for at least five years were recruited in our study. Pregnant and breastfeeding women, individuals who had acute and chronic inflammatory diseases, malignancy, or hematological disorders were excluded. Ultimately, we acquired complete data on 3,452 subjects. In the final analysis, 978 subjects were selected by computer-generated random numbers to detect soluble endoglin levels. The Institutional Review Board of the Fujian Provincial Hospital approved the study, which was performed according to the Declaration of Helsinki. All participants provided signed informed consent after they received a detailed description of the potential benefits and risks associated with the study.

The age, smoking habits, alcohol consumption, medical history (including hypertension, diabetes, CAD, cardiomyopathy, congenital heart disease, peripheral vascular disease, congestive heart failure, stroke, acute and chronic inflammatory diseases, malignancy, or hematological disorder) and medications were investigated using a questionnaire. Physical examinations included height, weight, and blood pressure, which was measured with a standard vertical mercury sphygmomanometer. Blood samples were collected after overnight fasting of at least 8 h. Standard laboratory evaluations determined the plasma levels of triglycerides, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), glycosylated hemoglobin (HbA1c), serum creatinine, and serum uric acid (SUA). Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared (kg/m²). Pulse pressure was estimated as the difference between the mean values of the systolic and diastolic blood pressure. The estimated glomerular filtration rate (eGFR) was calculated using Modification of Diet in Renal Disease method. Subjects who had a history of hypertension and were taking antihypertensive drugs were defined as hypertensive. Participants diagnosed with diabetes, currently taking anti-diabetic medications, or had an HbA1c ≥ 6.5% were defined as diabetic.

The soluble endoglin concentration in serum
samples was evaluated using an enzyme-linked immunosorbent assay method (Human CD105; Abcam, Cambridge, UK) according to the manufacturer’s instructions. The optical density was recorded using a microplate reader (Sunrise; Tecan Trading AG, Switzerland) at 450 nm. The standard curve was drawn using computer software. The soluble endoglin concentration of the corresponding sample was checked with the optical density value curve of the standard sample.

A single-blinded carotid artery exam was conducted by a single experienced sonographer using a high-resolution B-mode scanner (M-turbo; FUJIFILM SonoSite, Bothell, USA) with the subject in the supine position according to American Society of Echocardiography Guidelines. The cIMT was measured at 1 cm proximal to carotid bifurcation and along at least 1 cm of the axial length, recorded as the distance between the intimal-luminal and the medial-adventitial interfaces of the carotid artery wall represented as a double-line density on an ultrasound image. The mean cIMT values from the far walls of the bilateral common carotid arteries (mean-mean) were reported. The definition of elevated cIMT was an absolute cIMT value ≥ 0.9 mm. Carotid plaque was reported when the thickness of the most thickened region was 50% greater than that of the surrounding vessel wall or where cIMT was greater than 1.5 mm.

The 10-year ASCVD risk was estimated using the new Pooled Cohort Equations for non-Hispanic whites recommended by 2013 American College of Cardiology/American Heart Association. The equation was calculated from components of gender, age, treated or untreated SBP, TC, HDL-C, current smoking, and diabetes. According to the 10-year ASCVD risk, participants were stratified into two groups (<7.5%, low ASCVD risk; ≥ 7.5%, high ASCVD risk).

All statistical analyses were performed using R version 3.5.3 and MedCalc® statistical software. Continuous variables were presented as mean ± standard deviation, and categorical variables were expressed as frequencies and percentages. Comparisons between continuous and categorical variables were assessed using the analysis of covariance and chi-square test, respectively. The soluble endoglin levels were log-transformed before analysis. The participants’ demographic characteristics were presented in two groups according to the median of log-transformed soluble endoglin. The significant variables in covariance analysis, except for ASCVD risk and cIMT, were considered preliminary covariates of endoglin and included in multivariable regression analysis.

We computed Pearson correlations of soluble endoglin levels with 10-year ASCVD risk and cIMT. A receiver operating characteristic (ROC) curve was applied to evaluate the soluble endoglin level and the findings of carotid subclinical atherosclerosis (elevated cIMT and carotid plaque). We divided the subjects into two groups, at cutoff points determined according to the Youden index, for carotid subclinical atherosclerosis against log-transformed endoglin or 10-year ASCVD risk. Sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio for predicting atherosclerosis were reported in binary groups separately and both together in parallel or series manners.

Prognostic comparisons during models were done using Harrell’s concordance C-statistic, continuous net reclassification improvement (NRI), and integrated discrimination index (IDI) to evaluate the stratification of effects from 10-year ASCVD risk model to a complete model, including 10-year ASCVD risk, log-transformed soluble endoglin, HbA1c, eGFR, and BMI.

We also examined the linear relationship of cIMT with ASCVD risk and soluble endoglin by a multivariate-adjusted model with stepwise selection method. All reported P-values were two-tailed, and P < 0.05 was considered statistically significant.

Results
The study enrolled 978 subjects; 38.85% (n=380) were male and 61.15% (n=598) were female. The participants had a mean age of 57.24 years (±9.7). The mean 10-year ASCVD risk by the new Pooled Cohort Equations accounted for 10.04% (±12.35). The mean soluble endoglin level was 15.35 ng/ml (±6.64), and 395 subjects were defined as having high ASCVD risk (10-year risk ≥ 7.5%). Subjects in the high endoglin group manifested higher ASCVD risk than those in the low endoglin group (15.14 ± 14.71% vs. 4.93 ± 6.07%, P<0.001). The individuals with high soluble endoglin were significantly older, had higher SBP, diastolic blood pressure (DBP), pulse pressure, BMI, HbA1c, triglycerides, TC, LDL-C, eGFR, SUA, and had lower HDL-C. The cases of current smoking, alcohol consumption, hypertension, Diabetes mellitus, and antihypertensive therapy were higher in high endoglin group, and the difference was significant (P<0.001). The mean cIMT was significantly higher in the high ASCVD risk group than in the low risk group (0.91 ± 0.19 mm vs. 0.77 ± 0.15 mm, P<0.001). The high soluble endoglin group had a higher prevalence of CAD than the low group, but the difference showed no statistical significance.
Table 1. Baseline characteristics of study subjects

| Variable                        | Total   | Low group (<1.126 ng/ml) | High group (≥1.126 ng/ml) | p       |
|---------------------------------|---------|--------------------------|---------------------------|---------|
|                                | N       | 489                      | 489                       | -       |
| Age, years                      | 978     | 54.07 ± 8.54             | 60.41 ± 9.76              | <0.001  |
| SBP, mmHg                       | 134.62 ± 19.22 | 123.54 ± 14.25             | 145.71 ± 17.04              | <0.001  |
| DBP, mmHg                       | 80.67 ± 11.55 | 75.95 ± 9.70                   | 85.40 ± 11.55              | <0.001  |
| pulse pressure, mmHg            | 53.95 ± 14.09 | 47.59 ± 10.92                   | 60.31 ± 14.04              | <0.001  |
| BMI, kg/m²                      | 23.98 ± 3.08  | 23.59 ± 3.01                 | 24.37 ± 3.11               | <0.001  |
| HbA1c, %                        | 5.84 ± 1.07   | 5.76 ± 1.03                  | 5.92 ± 1.11                | 0.019   |
| TG, mmol/L                      | 1.66 ± 1.48   | 1.45 ± 1.28                  | 1.86 ± 1.63                | <0.001  |
| TC, mmol/L                      | 5.12 ± 1.08   | 4.97 ± 1.02                  | 5.27 ± 1.12                | <0.001  |
| HDL-C, mmol/L                   | 1.38 ± 0.36   | 1.42 ± 0.36                  | 1.33 ± 0.36                | <0.001  |
| LDL-C, mmol/L                   | 3.25 ± 1.15   | 3.06 ± 1.09                  | 3.43 ± 1.19                | <0.001  |
| eGFR, ml/min/1.73 m²            | 99.82 ± 26.96 | 102.40 ± 27.32                | 97.24 ± 26.36              | 0.003   |
| SUA, µmol/L                     | 329.99 ± 93.19 | 312.10 ± 87.28                  | 347.87 ± 95.55             | <0.001  |
| Soluble endoglin, ng/ml         | 15.35 ± 6.64  | 10.34 ± 1.96                 | 20.35 ± 5.85               | <0.001  |
| ASCVD risk, %                   | 10.04 ± 12.35 | 4.93 ± 6.07                   | 15.14 ± 14.71             | <0.001  |
| cIMT, mm                        | 0.84 ± 0.19   | 0.77 ± 0.15                  | 0.91 ± 0.19                | <0.001  |
| Male, n (%)                     | 380 (38.85)  | 151 (30.88)                 | 229 (46.83)                | <0.001  |
| Current smokers, n (%)          | 191 (19.53)  | 77 (15.75)                  | 114 (23.31)                | 0.003   |
| Alcohol, n (%)                  | 202 (20.65)  | 85 (17.38)                  | 117 (23.93)                | 0.012   |
| Diabetes mellitus, n (%)        | 147 (15.03)  | 50 (10.22)                  | 97 (19.84)                 | <0.001  |
| Hypertension, n (%)             | 266 (27.20)  | 43 (8.79)                   | 223 (45.60)                | <0.001  |
| Antihypertensive therapy, n (%) | 181 (18.51)  | 25 (5.11)                   | 156 (31.90)                | <0.001  |
| Coronary artery disease, n (%)  | 28 (2.86)    | 9 (1.84)                    | 19 (3.86)                  | 0.055   |

Quantitative variables are presented as means±standard deviation, qualitative variables are presented as numbers with percentages. ASCVD risk, 10-year predicted risk for atherosclerotic cardiovascular disease calculated by the new Pooled Cohort Equations; BMI, body mass index; cIMT: carotid intima-media thickness; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; SUA, serum uric acid; TC, total cholesterol; TG, triglycerides.

*p < 0.055. Table 1 shows more details of the comparison of characteristics. The multivariable regression showed that the independent determinants of log-transformed soluble endoglin were age, SBP, DBP, TC, HDL-C, and SUA, which were in partial accord with ASCVD parameters (Table 2).

Significant positive correlations between the soluble endoglin level with 10-year ASCVD risk (r = 0.543, P < 0.001) and cIMT (r = 0.457, P < 0.001) were presented by Pearson’s correlation analysis (Fig. 1).

Among the 978 participants, nearly half (47.14%, n = 461) had unilateral or bilateral elevated cIMT (mean cIMT ≥ 0.9 mm), and at least 1 carotid plaque was present in 354 subjects. The cutoff point of ASCVD risk was 9.34% for the elevated cIMT performance curve, and 9.46% for carotid plaque presence, both selected by the Youden index. Adopting the similar method, the cutoff point of log-transformed endoglin was set at 1.16 ng/ml for the elevated cIMT performance curve, and 1.17 ng/ml for carotid plaque presence. After categorizing individuals into binary endoglin level groups based on cutoffs, we found higher sensitivity for identifying carotid atherosclerosis than in groups divided by ASCVD risk. Adding the tests together in parallel will increase sensitivity and decrease specificity, and vice versa, in series (Table 3). For identifying elevated cIMT, the ASCVD risk model showed acceptable discrimination (C-statistics 0.698, 95%CI 0.668-0.726). As for carotid plaque, the ASCVD risk model showed fair discrimination (C-statistics 0.754, 95%CI 0.722-0.786). Evaluating the added value of endoglin to the ASCVD risk model showed significantly improved discrimination with analysis of C-statistics, continuous NRI, and IDI. The largest C-statistics were seen with the complete model,
Our results showed that soluble endoglin was significantly associated with a range of cardiovascular risk factors and remained positively correlated with carotid atherosclerosis after adjusting for confounding factors. We, for the first time, combined both soluble endoglin and ASCVD risk to recognize elevated cIMT and carotid plaque, which revealed a better sensitivity of 76.14% and 83.33% in a parallel manner, respectively.

To the best of our knowledge, this study, for the first time, reported serum soluble endoglin in a Chinese community population. Our results showed that soluble endoglin was significantly associated with a range of cardiovascular risk factors and remained positively correlated with carotid atherosclerosis after adjusting for confounding factors. We, for the first time, combined both soluble endoglin and ASCVD risk to recognize elevated cIMT and carotid plaque, which revealed a better sensitivity of 76.14% and 83.33% in a parallel manner, respectively.

Discussion

In the present study, we assessed the association between soluble endoglin, ASCVD risk, and carotid subclinical atherosclerosis in a Chinese community population. Our results showed that soluble endoglin was significantly associated with a range of cardiovascular risk factors and remained positively correlated with carotid atherosclerosis after adjusting for confounding factors. We, for the first time, combined both soluble endoglin and ASCVD risk to recognize elevated cIMT and carotid plaque, which revealed a better sensitivity of 76.14% and 83.33% in a parallel manner, respectively.

To the best of our knowledge, this study, for the first time, reported serum soluble endoglin in a Chinese community population. Our results showed that soluble endoglin was significantly associated with a range of cardiovascular risk factors and remained positively correlated with carotid atherosclerosis after adjusting for confounding factors. We, for the first time, combined both soluble endoglin and ASCVD risk to recognize elevated cIMT and carotid plaque, which revealed a better sensitivity of 76.14% and 83.33% in a parallel manner, respectively.

Fig. 1. Linear relationship between soluble endoglin levels and: (A) 10-year ASCVD risk (r = 0.543, P < 0.001), and (B) cIMT (r = 0.457, P < 0.001)

10-year ASCVD risk: 10-year predicted risk for atherosclerotic cardiovascular disease calculated by the new Pooled Cohort Equations; cIMT, carotid intima-media thickness.

Table 2. Multivariate linear regression analysis for log-transformed soluble endoglin levels

| Variable               | β     | SE   | standardized β | t    | P     |
|------------------------|-------|------|----------------|------|-------|
| Age, years             | 0.003 | <0.001 | 0.193          | 7.544 | <0.001 |
| SBP, mmHg              | 0.005 | <0.001 | 0.506          | 15.044 | <0.001 |
| DBP, mmHg              | 0.001 | <0.001 | 0.07           | 2.14  | 0.033 |
| BMI, kg/m²             | -0.002 | 0.001 | -0.038         | -1.538 | 0.124 |
| HbA₁c, %               | 0.007 | 0.004 | 0.04           | 1.683 | 0.093 |
| TG, mmol/L             | 0.003 | 0.003 | 0.027          | 1.02  | 0.308 |
| TC, mmol/L             | 0.022 | 0.006 | 0.135          | 3.835 | <0.001 |
| HDL-C, mmol/L          | -0.05 | 0.013 | -0.105         | -3.944 | <0.001 |
| LDL-C, mmol/L          | 0.002 | 0.005 | 0.014          | 0.416 | 0.677 |
| eGFR, ml/min/1.73 m²   | <0.001 | <0.001 | -0.045         | -1.852 | 0.064 |
| SUA, umol/L            | <0.001 | <0.001 | 0.063          | 2.481 | 0.013 |

Multivariate regression analysis excluded pulse pressure for the multicollinearity. 1 SD log-transformed soluble endoglin equals 0.175 ng/ml. SE, standard error; BMI: body mass index; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; SBP: systolic blood pressure; SUA: serum uric acid; TC: total cholesterol; TG: triglycerides.
results clarified that, in subjects with carotid subclinical atherosclerosis, soluble endoglin appeared to be high. Our result was similar to previous reports about elevated soluble endoglin levels in ischemic heart disease, peripheral vascular disease, and coronary disease\textsuperscript{14, 17). However, Cruz-Gonzalez\textsuperscript{19) and Saita E et al.\textsuperscript{20)} revealed soluble endoglin levels in acute myocardial infarction patients and coronary heart disease were low, even negatively associated with the severity of coronary heart disease. Those controversial results may have occurred because soluble endoglin increased in the early stage of atherosclerosis, due to endothelial damage, and decreased in a later stage, due to enhanced atherogenesis induced by more endoglin/TGF-\( \beta \) complexes\textsuperscript{18). Thus, the high level of serum partially consistent with previous studies in subjects with medical histories of hypertension, diabetes mellitus, or dyslipidemia\textsuperscript{15, 16, 25}. Blazquez-Medela et al.\textsuperscript{15) reported soluble endoglin levels were higher in those with high probability of 10-year cardiovascular risk by using the scale of the ESH-ESC guide 2007\textsuperscript{28). Not surprising, by applying the new Pooled Cohort Equations recommended by ACC/AHA, we demonstrate a significant positive correlation between the soluble endoglin level with 10-year ASCVD risk.

As a crucial result of our study, subjects with high endoglin levels were more likely to have elevated cIMT and carotid plaque. With adjusting for 10-year ASCVD, BMI and HbA\textsubscript{1c}, the relationship between soluble endoglin and cIMT was still significant. These results clarified that, in subjects with carotid subclinical atherosclerosis, soluble endoglin appeared to be high. Our result was similar to previous reports about elevated soluble endoglin levels in ischemic heart disease, peripheral vascular disease, and coronary disease\textsuperscript{14, 17). However, Cruz-Gonzalez\textsuperscript{19) and Saita E et al.\textsuperscript{20)} revealed soluble endoglin levels in acute myocardial infarction patients and coronary heart disease were low, even negatively associated with the severity of coronary heart disease. Those controversial results may have occurred because soluble endoglin increased in the early stage of atherosclerosis, due to endothelial damage, and decreased in a later stage, due to enhanced atherogenesis induced by more endoglin/TGF-\( \beta \) complexes\textsuperscript{18). Thus, the high level of serum

Table 3. Diagnostic performance of ASCVD risk and endoglin for predicting carotid subclinical atherosclerosis separately and together

|                      | sensitivity(%) | specificity(%) | +LR  | -LR  |
|----------------------|---------------|---------------|------|------|
| elevated cIMT        |               |               |      |      |
| ASCVD risk           | 54.66         | 72.34         | 1.98 | 0.63 |
| log-sEng parallel    | 66.38         | 64.60         | 1.88 | 0.52 |
| series connection     | 76.14         | 53.58         | 1.64 | 0.45 |
| carotid plaque       |               |               |      |      |
| ASCVD risk           | 59.04         | 80.93         | 3.10 | 0.51 |
| log-sEng parallel    | 75.42         | 75.48         | 3.08 | 0.33 |
| series connection     | 83.33         | 65.71         | 2.43 | 0.25 |
|                      | 51.13         | 90.71         | 5.50 | 0.54 |

Elevated cIMT, carotid intima-media thickness values ≥ 0.9 mm. ASCVD risk: 10-year predicted risk for atherosclerotic cardiovascular disease calculated by the new Pooled Cohort Equations; cIMT, carotid intima-media thickness; log-sEng, log-transformed soluble endoglin; +LR, positive likelihood ratio; -LR, negative likelihood ratio. Cutoff points in elevated cIMT: 9.34% for ASCVD risk, 1.16 for log-sEng; Cutoff points in carotid plaque: 9.46% for ASCVD risk, 1.17 for log-sEng; parallel connection: ASCVD risk higher than cutoff point or log-sEng higher than cutoff point. series connection: ASCVD risk higher than cutoff point together with log-sEng higher than cutoff point.

Table 4. Added value of endoglin to the ASCVD risk model in carotid subclinical atherosclerosis

|                      | C-statistics (95%CI) | P      | continuous NRI (95%CI) | P  | IDI (95%CI) | P     |
|----------------------|----------------------|--------|------------------------|----|-------------|-------|
| elevated cIMT        |                      |        |                        |    |             |       |
| Model 1              | 0.698 (0.665,0.731)  | -      | -                      | -  |             |       |
| Model 2              | 0.736 (0.704,0.767)  | 0.002  | 0.412 (0.289, 0.534)   | < 0.001 | 0.058 (0.043, 0.072) | < 0.001 |
| Model 3              | 0.748 (0.717,0.778)  | < 0.001 | 0.563 (0.442, 0.683)   | < 0.001 | 0.072 (0.056, 0.088) | < 0.001 |
| carotid plaque       |                      |        |                        |    |             |       |
| Model 1              | 0.754 (0.722,0.786)  | -      | -                      | -  |             |       |
| Model 2              | 0.842 (0.815,0.868)  | < 0.001 | 0.753 (0.631, 0.874)   | < 0.001 | 0.174 (0.148, 0.200) | < 0.001 |
| Model 3              | 0.844 (0.818,0.871)  | < 0.001 | 0.838 (0.719, 0.957)   | < 0.001 | 0.179 (0.152, 0.205) | < 0.001 |

P value, compared to Model 1. Model 1 included 10-year ASCVD risk. Model 2 included 10-year ASCVD risk and log-transformed soluble endoglin. Model 3 included 10-year ASCVD risk, log-transformed soluble endoglin, HbA\textsubscript{1c}, eGFR and BMI. Elevated cIMT, carotid intima-media thickness values ≥ 0.9 mm.10-year ASCVD risk, 10-year predicted risk for atherosclerotic cardiovascular disease calculated by the new Pooled Cohort Equations; cIMT, carotid intima-media thickness; eGFR, estimated glomerular filtration rate; IDI, integrated discrimination index; NRI, net reclassification index.
Erosclerosis need to be assessed in new investigations. Previous studies indicated high carotid IMT or carotid plaque to be a strong predictor of cardiovascular disease. Since the new ASCVD risk calculator was developed, two recent analyses of large Asian subjects have demonstrated that carotid IMT correlated with the new 10-year ASCVD risk score. In agreement with those studies, in the present study, 10-year ASCVD risk was positively correlated with cIMT and carotid atherosclerosis. In addition, a prospective study with a small sample showed that chronic kidney disease, left ventricular ejection fraction, and serum endoglin were predictors of major adverse cardiovascular events (congestive heart failure, acute myocardial infarction, stroke, and sudden cardiac death). Based on above findings, we found that a model incorporating endoglin and 10-year ASCVD would contribute to recognizing carotid subclinical atherosclerosis. Not surprisingly, we demonstrate an increased carotid atherosclerosis need to be assessed in new investigations.

Previous studies indicated high carotid IMT or carotid plaque to be a strong predictor of cardiovascular disease. Since the new ASCVD risk calculator was developed, two recent analyses of large Asian subjects have demonstrated that carotid IMT correlated with the new 10-year ASCVD risk score. In agreement with those studies, in the present study, 10-year ASCVD risk was positively correlated with cIMT and carotid atherosclerosis. In addition, a prospective study with a small sample showed that chronic kidney disease, left ventricular ejection fraction, and serum endoglin were predictors of major adverse cardiovascular events (congestive heart failure, acute myocardial infarction, stroke, and sudden cardiac death). Based on above findings, we found that a model incorporating endoglin and 10-year ASCVD would contribute to recognizing carotid subclinical atherosclerosis. Not surprisingly, we demonstrate an increased carotid atherosclerosis need to be assessed in new investigations.

Table 5. Linear regression analysis showing association of soluble endoglin level and ASCVD risk with cIMT

| Variable          | Unadjusted | Multivariate model | Multivariate model |
|-------------------|------------|--------------------|--------------------|
|                   |            | Model 1            | Model 2            |
|                   | β          | t                  | P                  | β          | t                  | P                  |
| ASCVD risk        | 0.006      | 14.030             | <0.001             | 0.004      | 7.966              | <0.001             |
| log-sEng          | 0.485      | 16.044             | <0.001             | 0.360      | 10.821             | <0.001             |

Model 1 included 10-year ASCVD risk (or log-transformed endoglin). Model 2 included HbA1c, BMI, 10-year ASCVD risk and log-transformed endoglin. 10-year ASCVD risk: 10-year predicted risk for atherosclerotic cardiovascular disease calculated by the new Pooled Cohort Equations; cIMT, carotid intima-media thickness; log-sEng, log-transformed soluble endoglin.
mixed effects from other risk factors.

The strength of our study is the new atherosclerosis marker endoglin and efficient 10-year ASCVD risk. By investigating a range of cardiovascular risk factors in a Chinese community population, we thoroughly explored the determinants of soluble endoglin and pioneered models, including serum endoglin and 10-year ASCVD risk, to improve recognition for carotid atherosclerosis. Our study also has a few limitations. First, the Pooled Cohort Equations was originally developed in African Americans and non-Hispanic Whites, which limited their applicability to other populations. We did not apply the ChinaPAR to assess ASCVD risk due to insufficient information. Second, the data presented here are cross-sectional and would not clarify the causal relationship. Therefore, a larger cohort would be required. Third, carotid subclinical atherosclerosis as a single indicator of atherosclerosis or subclinical atherosclerosis would generate certain degrees of bias. Hence, the relationship between atherosclerosis and soluble endoglin levels should be detected in more vascular beds.

Conclusion

Soluble endoglin is independently related with age, SBP, DBP, TC, HDL-C, SUA, and 10-year ASCVD risk, remained positively correlative with carotid subclinical atherosclerosis after adjusting for confounding factors. The combination of ASCVD risk and endoglin levels detects carotid atherosclerosis more often.

Acknowledgments and Notice of Grant Support

Startup funding for scientific research, Fujian Medical University (Grant number: 2016QH122), Major project of Fujian science and technology program (2016YZ0001-1), Pilot project of Fujian science and technology program (2017Y0016), Excellent Young Doctor Training Program in Fujian Provincial Health System (2013–ZQN-ZD-4), Project of National Health and Family Planning Commission for Screening and Intervention Programs for High Risk Population of Stroke (GN-2016F0006).

COI

None.

References

1) Abubakar I, Tillmann T and Banerjee A. Global, regional,
Endoglin and ASCVD

and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015; 385: 117-171

2) Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, Li Y, Wang L, Liu Y and Yin P. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet, 2016; 387: 251-272

3) Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, Wan X, Yu S, Jiang Y and Naghavi M. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet, 2013; 381: 1987-2015

4) Bots ML, Hoes AW, Koudstaal PJ, Hofman A and Grobbbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation, 1997; 96: 1432-1437

5) Touboul P-J, Labreuche J, Vicaud E and Amarenco P. Carotid intima-media thickness, plaques, and Framingham risk score as independent determinants of stroke risk. Stroke, 2005; 36: 1741-1745

6) Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, Volick K, Boerwinkle E and Ballantyne CM. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Heart Assoc, 2010; 55: 1600-1607

7) Naqvi TZ, Mendoza F, Raffi F, Gransar H, Mendoza F, Rafii F, Gransar H, Guerra M. Targeting cancer vasculature via endoglin/CD105: a transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem, 1992; 267: 19027-19034

8) Stone NJ, Robinson JG, Mezzina CNB, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D and Lloyd-Jones DM. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014; 63: 2889-2934

9) Lee D-G, Han J-H, Kwon K-Y, Kim J-H, Han K-H and Lee E-J. Association of 10-year atherosclerotic cardiovascular disease risk score with carotid intima-media thickness and plaque. Korean J Fam Med, 2015; 36: 310

10) Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, Masague J and Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem, 1992; 267: 19027-19030

11) Fonsatti E, Nicolay HJ, Altomonte M, Covre A and Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumors. Cardiovasc Res, 2009; 86: 12-19

12) Venkatessa S, Toporsian M, Lam C, Hanai J-i, Mammoth T, Kim YM, Bohlod Y, Lim K-H, Yuan H-T and Libermann TA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med, 2006; 12: 642

13) De Vivo A, Bavier A, Giordano D, Todarello G, Corrado F and D’anna R. Endoglin, PI GF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand, 2008; 87: 837-842

14) Blann A, Wang JM, Wilson P and Kumar S. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis, 1996; 120: 221-226

15) Blázquez-Medela AM, García-Ortiz L, Gómez-Marcos MA, Recio-Rodríguez JL, Sánchez-Rodríguez A, López-Novoa JM and Martínez-Salgado C. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med, 2010; 8: 86

16) Blaha M, Cermanova M, Blaha V, Jarolim P, Andrys C, Blazek M, Maly J, Smolej L, Zajic J and Masin V. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis, 2008; 197: 264-270

17) Rathouska J, Jezkova K, Nemecová I and Nachtigal J. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis, 2015; 243: 383-388

18) Li C, Bethell H, Wilson P, Bhatnagar D, Walker M and Kumar S. The significance of CD105, TGFβ and CD105/TGFβ complexes in coronary artery disease. Atherosclerosis, 2000; 152: 249-256

19) Cruz-Gonzalez I, Pabón P, Rodríguez-Barbero A, Martín-Moreiras J, Pericacho M, Sánchez PL, Ramirez V, Sánchez-Ledesma M, Martín-Herrero F and Jiménez-Candil J. Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction. J Cell Mol Med, 2008; 12: 955-961

20) Saita E, Miura K, Suzuki-Sugihara N, Miyata K, Ikemura N, Ohmori R, Ikegami Y, Kishimoto Y, Kondo K and Momiyama Y. Plasma soluble endoglin levels are inversely associated with the severity of coronary atherosclerosis—brief report. Arterioscler Thromb Vasc Biol, 2017; 37: 49-52

21) Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med, 1999; 130: 461-470

22) Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr J, Jones DW, Materson BJ, Oparil S and Wright Jr JT. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA, 2003; 289: 2560-2571

23) Marathe PH, Gao HX and Close KL. American Diabetes Association Standards of Medical Care in Diabetes 2017. J Diabetes, 2017; 9: 320-324

24) Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM and Post WS. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr, 2008; 21: 93-111

25) Naqvi TZ and Lee M-S. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging, 2014; 7: 1025-1038

26) Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’agostino RB, Gibbons R, Greenland P, Lackland DT,
Levy D and O’donnell CJ. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014; 63: 2935-2959

27) Doghish AS, Bassiony AA, Mahfouz MH, El-Aziz HGA and Zakaria RY. Plasma endoglin in Type2 diabetic patients with nephropathy. Diabetes Metab Syndr, 2019; 13: 764-768

28) Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Haggerty AM, Kjeldsen SE and Laurent S. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 2007; 28: 1462-1536

29) Çelik N, Cinaz P, Bideci A, Derinkuyu B, Emekşiz HC, Döger E, Damar Ç, Yüce Ö and Çamurdan O. Endoglin and obestatin levels, cardiometabolic risk factors and subclinical atherosclerosis in children aged 10–18 years. J Pediatr Endocrinol Metab, 2016; 29: 1173-1180

30) Luque A, Slevin M, Turu MM, Juan-Babot O, Badimon L and Krupinski J. CD105 positive neovessels are prevalent in early stage carotid lesions, and correlate with the grade in more advanced carotid and coronary plaques. J Angiogenes Res, 2009; 1: 6

31) Kandula NR, Kanaya AM, Liu K, Lee JY, Herrington D, Hulley SB, Persell SD, Lloyd-Jones DM and Huffman MD. Association of 10-year and lifetime predicted cardiovascular disease risk with subclinical atherosclerosis in South Asians: findings from the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study.

J Am Heart Assoc, 2014; 3: e001117

32) Ikemoto T, Hojo Y, Kondo H, Takahashi N, Hirose M, Nishimura Y, Katsuki T, Shimada K and Kario K. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels, 2012; 27: 344-351

33) Bots ML, Hofman A, Grobbee DE. Increased common carotid intima-media thickness. Adaptive response or a reflection of atherosclerosis? Findings from the Rotterdam Study. Stroke, 1997; 28: 2442-2447

34) Moskau S, Golla A, Grothe C, Boes M, Pohl C, Klockgether T. Heritability of carotid artery atherosclerotic lesions: an ultrasound study in 154 families. Stroke, 2005; 36: 5-8

35) Zureik M, Temmar M, Adamopoulos C, Bureau JM, Courbon D, Thomas F, Bean K, Touboul PJ, Ducimetière P, Benetos A. Carotid plaques, but not common carotid intima-media thickness, are independently associated with aortic stiffness. J Hypertens, 2002; 20: 85-93

36) Nikuei P, Rajaei M, Malekzadeh K, Nejatizadeh A, Mohseni F and AtashAbParvar A. Accuracy of soluble endoglin for diagnosis of preeclampsia and its severity. Iran Biomed J, 2017; 21: 312

37) Olatunji LA, Areola ED, Badmus OO. Endoglin inhibition by sodium acetate and flutamide ameliorates cardiac defective G6PD-dependent antioxidant defense in gestational testosterone-exposed rats. Biomed Pharmacother, 2018; 107: 1641-1647

38) Charytan DM, Helfand AM, MacDonald BA, Cinelli A, Kalluri R, Zeisberg EM. Circulating endoglin concentration is not elevated in chronic kidney disease. PloS one, 2011; 6(8): e23718
**Supplementary Table 1.** Baseline characteristics of study subjects

| Variable                      | selected          | not selectd       | P-value |
|-------------------------------|-------------------|-------------------|---------|
| N                             | 978               | 2,474             | -       |
| Age, years                    | 57.24±9.70        | 56.70±9.90        | 0.141   |
| SBP, mmHg                     | 134.62±19.22      | 134.50±18.96      | 0.869   |
| DBP, mmHg                     | 80.67±11.55       | 80.59±11.67       | 0.845   |
| pulse pressure, mmHg          | 53.95±14.09       | 53.92±13.97       | 0.949   |
| BMI, kg/m²                    | 23.98±3.08        | 24.05±3.21        | 0.546   |
| HbA1c, %                      | 5.84±1.07         | 5.83±1.06         | 0.851   |
| TG, mmol/L                    | 1.66±1.48         | 1.67±1.42         | 0.77    |
| TC, mmol/L                    | 5.12±1.08         | 5.10±1.07         | 0.716   |
| HDL-C, mmol/L                 | 1.38±0.36         | 1.39±0.37         | 0.205   |
| LDL-C, mmol/L                 | 3.25±1.15         | 3.26±1.09         | 0.655   |
| eGFR, ml/min/1.73 m⁻³         | 99.82±26.96       | 98.61±21.20       | 0.209   |
| SUA, umol/L                   | 329.99±93.19      | 331.27±89.08      | 0.712   |
| 10-year ASCVD risk, %         | 10.04±12.35       | 9.86±11.93        | 0.704   |

| Male, n (%)                  | 380 (38.85)       | 1,008 (40.74)     | 0.314   |
| Current smokers, n (%)       | 191 (19.53)       | 520 (21.02)       | 0.33    |
| Alcohol, n (%)               | 202 (20.65)       | 517 (20.90)       | 0.729   |
| Diabetes mellitus, n (%)     | 147 (15.03)       | 374 (15.12)       | 0.949   |
| Hypertension, n (%)          | 266 (27.20)       | 681 (27.53)       | 0.846   |
| Antihypertensive therapy, n (%) | 181 (18.51) | 488 (19.73) | 0.415 |

Quantitative variables are presented as means±standard deviation, qualitative variables are presented as numbers with percentages. 10-year ASCVD risk: 10-year predicted risk for atherosclerotic cardiovascular disease calculated by the new Pooled Cohort Equations; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; TG: triglycerides; TC: total cholesterol; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; eGFR: estimated glomerular filtration rate; SUA: serum uric acid.